Hester Biosciences Q4 FY26 Results: PAT Rs 16.54 Cr, Revenue Rs 100.11 Crore

Hester Biosciences Q4 FY26 results were declared on May 15, 2026, at the board of directors meeting. Hester Biosciences reported PAT of Rs 16.54 crore for the quarter ended March 31, 2026, up 974.0% YoY from Rs 1.54 crore in Q4 FY25, on revenue of Rs 100.11 crore. Hester Biosciences is a animal health vaccines and nutrition company. Investors tracking Hester Biosciences Q4 FY26 will find complete financial analysis, segment performance, and FY27 outlook in this article.

Click Here – Get Free Investment Predictions

Hester Biosciences Q4 FY26 Financial Highlights

Hester Biosciences Q4 FY26 Performance Analysis

Hester Biosciences Q4 FY26 results reflect the company’s operational performance during the January to March 2026 quarter. Hester Biosciences operates in the animal health vaccines and nutrition space, a sector that has seen strong demand tailwinds in FY26 driven by domestic consumption growth, government capex, and India’s infrastructure buildout. The Q4 results cap the full FY26 year and set the baseline for FY27 guidance.

The quarter’s profitability improvement reflects better operating leverage, pricing discipline, and cost management. Investors tracking Hester Biosciences Q4 FY26 will monitor FY27 revenue visibility and management commentary on margin sustainability. Track Hester Biosciences on the Univest Screener for live data and analyst ratings.

Key Business Factors for Hester Biosciences Q4 FY26

Sectoral Demand and Revenue Momentum

Hester revenue of Rs 100.11 crore reflects the company’s ability to execute in a competitive animal health vaccines and nutrition environment. Q4 is typically the strongest quarter for most Indian companies as year-end government spending, project completions, and festival-driven demand peak. The revenue trajectory for FY27 will be determined by order book conversions, new contract wins, and demand visibility from key customers.

Margin and Profitability Outlook

The company PAT of Rs 16.54 crore reflects profitable operations with improving margins across the business. EBITDA margin trends and operating leverage will be key metrics to watch as FY27 guidance is finalised.

FY27 Guidance and Business Outlook

Following the firm results, management commentary on FY27 revenue guidance, capital expenditure plans, dividend policy, and strategic priorities will be the key near-term catalysts for the stock. India’s robust GDP growth of 6.5%+ and the government’s sustained infrastructure and consumption push create a positive macro backdrop for FY27 across most sectors. Monitor Hester Biosciences financials in real time on the Univest Screener.

Check the Univest Screener for live data

Download the Univest iOS App or Univest Android App to track live prices and SEBI-registered analyst research.

Frequently Asked Questions on Hester

What is the company PAT?

Ans. Hester reported PAT of Rs 16.54 crore up 974.0% YoY from Rs 1.54 crore in Q4 FY25. Results were declared on May 15, 2026. Full details are available from NSE/BSE regulatory filings. Verify all numbers before investing.

What is the company revenue?

Ans. The firm’s revenue from operations was Rs 100.11 crore for the quarter ended March 31, 2026. Track real-time financials on the Univest Screener.

When were Hester results announced?

Ans. The company results were announced on May 15, 2026, at the board of directors meeting approving audited financial statements for Q4 and the full year ended March 31, 2026.

What sector does Hester Biosciences operate in?

Ans. Hester Biosciences operates in the animal health vaccines and nutrition sector. Download the Univest iOS App or Univest Android App to track Hester Biosciences and get SEBI-registered research.

Is Hester Biosciences a good investment after Q4 FY26?

Ans. Investment decisions should be based on comprehensive analysis of fundamentals, sector dynamics, valuation, and individual risk appetite. This article does not constitute investment advice. Consult a SEBI-registered financial advisor before investing. This content is for educational purposes only.

Investments in securities are subject to market risk. This content is for educational purposes only and does not constitute investment advice.